Market Access

Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.

Accessia Health’s Tiara Green says Part D reforms eased drug costs, but premiums, deductibles and payer policies still limit patient access.

The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.

DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years beginning on or after July 1, 2027.

EVERSANA is folding Estima Scientific's AI-powered HEOR tools into its market access offerings as its CEO says evidence planning must start earlier.

Walgreens adds GLP-1 coverage navigation, Medicare Bridge support and pharmacist outreach to its virtual weight management service.

With a lawsuit, a House delay bill and drugmaker intervention motions in play, here's where HRSA's 340B rebate pilot stands ahead of Jan. 1.

Epic's Prescription Marketplace, due summer 2027, will show pharmacy cash prices next to insured costs before a prescription is sent.

PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.

Inside the October 2026 issue: why splitting MMR takes years, why payers cite a price that does not bind them, and what pricing rules broke.

Waltz Health and Fresenius Kabi will offer three biosimilars through a direct-to-payer model that bypasses traditional wholesaler and PBM rebate channels.

With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.

CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.

An FTC settlement moved one PBM aggregator onshore, but manufacturers still lack contract-level clarity on what affiliated fees actually buy.

Pharma pricing shifts beyond PBM rebates as Medicare and cash channels reshape launches, WAC cuts and access strategies.